NORTHWEST BIOTHERAPEUTICS INC (NWBO) Northwest Biotherapeutics, Inc. (NWBO) is a biotechnology firm that creates personalized immune-based treatments for various cancers, operating both within the United States and internationally. Their product pipeline relies on DCVax, a proprietary technology platform. This platform harnesses a patient's own activated dendritic cells to stimulate their immune system to combat cancerous cells. The company's leading therapeutic candidate, DCVax-L, has successfully completed Phase III clinical trials targeting Glioblastoma multiforme, an aggressive form of brain cancer. Additionally, Northwest Biotherapeutics is progressing DCVax-Direct through Phase I/II clinical studies, focusing on the treatment of inoperable solid tumors. Founded in 1996, the company's headquarters are situated in Bethesda, Maryland.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Northwest Biotherapeutics, Inc. OTC:NWBO Healthcare · Biotechnology
Mkt Cap $270.53M
EV -
SI 3.9%
Net Cash/Sh -
Prev close $0.1462 +1.23%Open $0.1480 +0.88%Now $0.1493 VOL 5.2M $ Vol $753K RVOL 1.17x
Mkt Cap $270.53M
EV -
VOL 5.2M sh
$ Vol $753K
RVOL 1.17×
SI 3.9%
Net Cash/Sh -
Press Release
Northwest Biotherapeutics Announces Expansion of Its Technical Team
Northwest Biotherapeutics expanded its US technical team with hires in QA/regulatory affairs, IT, and investor relations while eliminating non-essential positions, keeping operating costs in the same range. The company is prioritizing scale-up of US manufacturing capacity as back-up for UK production and preparations for clinical trials beyond brain cancer.
• 22d ago AI analysis › Press Release
Northwest Biotherapeutics and the UK National Health Service Blood and Transplant Announce Collaboration to Support DCVax®-L Production
Northwest Biotherapeutics and NHS Blood and Transplant announced a collaboration to support UK production of DCVax-L, with NHSBT teams performing leukapheresis and specialist cell processing. The model initially covers Leeds and Oxford, with a phased expansion to additional NHSBT locations across England under exploration alongside Advent Bioservices.
• 1mo ago AI analysis › Press Release
Northwest Biotherapeutics Announces Keynote Presentation on Harnessing Immunity: A Personalized, Multi-Target Approach to Cancer At the UK National Health Service Annual Oncology Conference
Northwest Biotherapeutics' Chief Technical Officer Dr. Marnix Bosch will deliver an invited keynote at the UK NHS CancerCare Oncology Conference on October 6. The talk covers the new era of cancer vaccines and the company's DCVax platform, including clinical trial results and potential combination treatments; slides will be posted to the company website afterward.
• 1mo ago AI analysis › Press Release
Northwest Biotherapeutics Announces MOU for Collaboration With the Saudi Pharmaceutical Industries and Medical Appliance Company
Northwest Biotherapeutics signed a non-binding Memorandum of Understanding with SPIMACO, a leading Saudi pharma company, to commercialize DCVax-L for glioblastoma in Saudi Arabia and potentially the MENA region. Under the revenue-sharing framework, SPIMACO will handle regulatory interactions with the SFDA and manage marketing and sales, while Northwest Biotherapeutics retains all IP and supplies the product.
• 3mo ago AI analysis › Press Release ● Major
Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses
Independent analyses of the Phase III DCVax-L trial for glioblastoma reveal that the treatment's survival extension was likely underestimated in the original cohort-based review. Using individual patient data, statisticians found a median survival advantage of 4.9 to 6.3 months, significantly higher than the 2.8 months previously reported. The updated Hazard Ratios ranged from 0.69 to 0.77 with p-values between 0.004 and 0.027, indicating a statistically significant reduction in the risk of death. Sensitivity analyses confirmed that these results were not driven by hidden imbalances between the DCVax-L patients and control groups.
• 4mo ago AI analysis › Press Release
Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting
Northwest Biotherapeutics announced that CTO Dr. Marnix Bosch will present data at the British Neuro-Oncology Society meeting showing DCVax-L survival extension using propensity score matching. The presentation focuses on the 331-patient Phase III trial for glioblastoma, for which a Marketing Authorization Application is currently under review in the UK.
• 4mo ago AI analysis › Press Release
Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform
prnewswire.com • 6mo ago Press Release
Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic
Northwest Biotherapeutics is establishing a dedicated leukapheresis clinic at The London Welbeck Hospital to proactively address capacity constraints and support the scale-up of its DCVax programs. The facility is designed to handle 4 patients per day with built-in flexibility for extended hours and weekend operations, with buildout expected to finish by June.
• 6mo ago AI analysis ›